FDA Assigns Priority Review Status for Sanofi Aventis' Multaq

In Cardio
Mon, 25 Aug 2008

The priority review is granted to applications in which a new indication or new drug product, if
approved, has a potential to present a safe and effective therapy where no satisfactory alternative
exists compared to currently available therapies or marketed products. A registration dossier is also under regulatory review by the European Medicines Agency (EMEA) for a Marketing Authorization Application.

«« Test for Heart Transplant Patients Approved

Recent Studies Inform Cost-Effective Heart Bypass Surgery »»

Latest Articles

Decision-Making in the ICU
- Journal Article
- 19/04/2024
Decision-making in the ICU is a multifaceted process that involves clinical assessment, collaboration among multidisciplinary teams, ethical considerations, evidence-based practice, communication, and continuous adaptation to evolving clinical scenarios. Balancing the complex factors requires
READ MORE
Dealing With Uncertainty in ICU Decision-Making: A Practical Guide
- Journal Article
- 19/04/2024
When the stakes are high, and the path ahead is uncertain, the decisions made, especially if a patient continues to worsen, can be sources of self-torment and can haunt us for a long time. Our goal is to suggest ways to steer decision-making for intensivists in the face of uncertainty by prop
READ MORE
The Least Bad Decision: Crisis Standards of Care After the Pandemic
- Journal Article
- 19/04/2024
COVID-19 was an emergency that lasted for years and left few regions of the world untouched. The pandemic shone a spotlight on both the strengths and weaknesses of our disaster planning. What worked, what did not, and how can we better plan for future emergencies? The COVID-19 pandemic fo
READ MORE

The priority review is granted to applications in which a new indication or new drug product, ifapproved, has a potential to present a safe and effective...